An Non-randomized Open-label, Multicenter Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Preliminary Efficacy of BA1106 in Participants With Advanced Solid Tumors
Latest Information Update: 11 Nov 2024
At a glance
- Drugs BA 1106 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Luye Pharma Group; Shandong Boan Biotechnology
- 08 Nov 2024 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 08 Nov 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Dec 2025.
- 12 Apr 2023 Status changed from not yet recruiting to recruiting.